Halozyme Therapeutics, Inc. number of employees

Halozyme Therapeutics, Inc. reported 423 employees at December 31, 2025 in its latest annual report, up 73 (20.9%) on the year before. That compares with 145 at December 31, 2021. Revenue per employee was $3.3m.

Headcount by year

Fiscal year end	Employees	Change	Revenue per employee	Source
December 31, 2025	423	+73 (20.9%)	$3.3m	10-K, filed February 17, 2026
December 31, 2024	350	−23 (6.2%)	$2.9m	10-K, filed February 18, 2025
December 31, 2023	373	−20 (5.1%)	$2.2m	10-K, filed February 20, 2024
December 31, 2022	393	+248 (171.0%)	$1.7m	10-K, filed February 21, 2023
December 31, 2021	145	—	$3.1m	10-K, filed February 22, 2022

What the annual reports say

As of February 10, 2026, we had 423 full-time employees. 2025 annual report
As of February 11, 2025, we had 350 full-time employees. 2024 annual report
As of February 12, 2024, we had 373 full-time employees. 2023 annual report
As of February 14, 2023, we had 393 full-time employees. 2022 annual report
As of February 14, 2022, we had 145 full-time employees. 2021 annual report

Headcount as the company states it in Item 1 of its annual report (some count full-time equivalents or exclude part-time and temporary staff), at the date it gives. Years where the report states no clear total are left out rather than estimated. Changes can reflect acquisitions and disposals as well as hiring and job cuts.

Compare with peers

Head to head: ALKS vs HALO HALO vs INSM HALO vs MDGL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Halozyme Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Halozyme Therapeutics, Inc.